GH Research (NASDAQ:GHRS) Trading Down 7.4% – Time to Sell?

Shares of GH Research PLC (NASDAQ:GHRS) traded down 7.4% during trading on Friday . The company traded as low as $11.34 and last traded at $11.34. 24,727 shares were traded during trading, a decline of 95% from the average session volume of 511,182 shares. The stock had previously closed at $12.25.

Analysts Set New Price Targets

GHRS has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of GH Research in a research note on Monday, January 27th. Guggenheim began coverage on shares of GH Research in a research report on Thursday, March 13th. They set a “buy” rating and a $32.00 price target on the stock. Stifel Nicolaus upped their price target on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Royal Bank of Canada initiated coverage on GH Research in a research note on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Cantor Fitzgerald began coverage on GH Research in a research note on Thursday, February 13th. They issued an “overweight” rating and a $14.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, GH Research has a consensus rating of “Buy” and a consensus target price of $30.86.

GH Research Price Performance

The firm has a market capitalization of $575.43 million, a PE ratio of -14.00 and a beta of 0.94. The company has a 50-day moving average price of $11.76 and a 200 day moving average price of $9.35.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. As a group, research analysts anticipate that GH Research PLC will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

Several institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets bought a new position in shares of GH Research in the 4th quarter valued at about $44,000. Two Sigma Investments LP purchased a new position in shares of GH Research in the 4th quarter worth approximately $117,000. Millennium Management LLC bought a new position in shares of GH Research during the 4th quarter valued at approximately $145,000. AdvisorShares Investments LLC raised its holdings in GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after buying an additional 4,806 shares during the period. Finally, Northern Trust Corp lifted its position in GH Research by 26.8% in the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after buying an additional 8,641 shares during the last quarter. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).